Riskpilot← Back to searchSign inGet full accessPHARMA-TRADE A/S
A/SActiveCVR 87339815Skaaremosevej 11-14Manufacture of perfumes and toilet preparations · NACE 2042Est. 19843 employees
Revenue 2024
DKK 0
EBITDA margin
—
-95% vs 2023
Equity ratio
100.0%
Financial strength
Net profit 2024
DKK 43,1M
+26% vs 2023
| Revenue | DKK 0 | — |
| EBITDA | DKK -82K | -95% |
| Net profit | DKK 43,1M | +26% |
| Total assets | DKK 272,8M | +9% |
| Equity | DKK 272,8M | +9% |
| Employees | 3 | — |
Legal name
PHARMA-TRADE A/S
CVR number
87339815
Legal form
Aktieselskab
NACE code
2042 · Manufacture of perfumes and toilet preparations
Founded
11. april 1984
Share capital
DKK 3.000.000
Employees
3 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af en direktør alene eller af to bestyrelsesmedlemmer i forening eller af den samlede bestyrelse.
Company purpose
Selskabets formål er at drive handel, fabrikation samt finansiering og anden i forbindelse dermed stående virksomhed
Address
Skaaremosevej 11-14
Email
rsa@persano.dk
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 1999 | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — | — | — | — | — | — | 3.034 | 1.526 | 1.461 | 1.758 | 2.064 | 1.839 | 1.388 | 1.323 | 62 | 0 | 0 | 0 | 0 |
| Staff expenses | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -1.641 | -1.659 | -1.683 | -1.690 | -1.693 | -1.715 | -1.741 | -1.745 | -0 | -0 | -0 | -0 | -0 |
| EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | -391 | -234 | -400 | -1.650 | 325 | 64 | -426 | -489 | -67 | -58 | -18 | -42 | -82 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -45 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | -391 | -279 | -400 | -1.650 | 325 | 64 | -426 | -489 | -67 | -58 | -18 | -42 | -82 |
| Net financials | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 24.104 | 30.250 | 26.961 | 29.507 | 33.393 | 29.586 | 22.769 | 30.547 | 41.109 | 46.502 | 28.061 | 34.896 | 43.757 |
| Profit before tax | — | — | — | — | — | — | — | — | — | — | — | — | — | 23.713 | 29.971 | 26.561 | 29.506 | 33.718 | 29.650 | 22.344 | 30.058 | 41.042 | 46.444 | 28.043 | 34.854 | 43.675 |
| Tax | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -326 | -64 | 123 | 55 | 41 | -27 | -122 | -117 | -37 | 3 | 28 | 500 | 533 |
| Net profit | — | — | — | — | — | — | — | — | — | — | — | — | — | 24.040 | 30.035 | 26.438 | 27.802 | 33.677 | 29.677 | 22.465 | 30.175 | 41.078 | 46.441 | 28.015 | 34.354 | 43.142 |
| Item | 1999 | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 170.343 | 184.563 | 182.997 | 205.837 | 220.953 | 221.384 | 217.619 | 225.086 | 234.374 | 246.923 | 238.104 | 251.405 | 272.807 |
| Equity | — | — | — | — | — | — | — | — | — | — | — | — | — | 142.210 | 157.713 | 153.582 | 184.461 | 202.117 | 208.548 | 206.554 | 214.966 | 233.216 | 242.438 | 238.089 | 251.385 | 272.786 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 28.133 | 26.850 | 29.415 | 21.376 | 18.837 | 12.836 | 11.065 | 10.120 | 1.158 | 4.484 | 15 | 20 | 21 |
| Total debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 28.133 | 26.850 | 29.415 | 21.376 | 18.837 | 12.836 | 11.065 | 10.120 | 1.158 | 4.484 | 15 | 20 | 21 |
EBITDA margin
-8228200.0%
This company
15.8%
Market median
-52077315% vs market
19992024
Equity ratio
100.0%
This company
38.2%
Market median
+162% vs market
19992024
Return on equity
15.8%
This company
18.4%
Market median
+14% vs market
19992024
Net profit margin
4314218500.0%
This company
8.1%
Market median
+53261956690% vs market
19992024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
19992024
Debt / equity
0.00×
This company
0.62×
Market median
+100% vs market
19992024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via CVR / Virk · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via CVR / Virk · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via CVR / Virk · Period 2012-01-01 – 2012-12-31
- Annual report 2011Filed via CVR / Virk · Period 2011-01-01 – 2011-12-31
- Annual report 2010Filed via CVR / Virk · Period 2010-01-01 – 2010-12-31
- Annual report 2009Filed via CVR / Virk · Period 2009-01-01 – 2009-12-31
- Annual report 2008Filed via CVR / Virk · Period 2008-01-01 – 2008-12-31
- Annual report 2007Filed via CVR / Virk · Period 2007-01-01 – 2007-12-31
- Annual report 2006Filed via CVR / Virk · Period 2006-01-01 – 2006-12-31
- Annual report 2005Filed via CVR / Virk · Period 2005-01-01 – 2005-12-31
- Annual report 2004Filed via CVR / Virk · Period 2004-01-01 – 2004-12-31
- Annual report 2003Filed via CVR / Virk · Period 2003-01-01 – 2003-12-31
- Annual report 2002Filed via CVR / Virk · Period 2002-01-01 – 2002-12-31
- Annual report 2001Filed via CVR / Virk · Period 2001-01-01 – 2001-12-31
- Annual report 2000Filed via CVR / Virk · Period 2000-01-01 – 2000-12-31
- Annual report 1999Filed via CVR / Virk · Period 1999-01-01 – 1999-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
HO Management | Management | 1999 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2024 | — | — | |
| Board of Directors | 1984 | — | — | |
| Board of Directors | 2024 | — | — | |
| Chairman | 1999 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
DANYL FINANS A/S | Company | 50.0% | 50.0% | 2009 |
PIF Holding ApS | Company | 50.0% | 50.0% | 2009 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
J Overgaard Holding ApS
PHARMA-TRADE A/S Board members of PHARMA-TRADE A/S also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Henrik Overgaard | Management | 0 companies |
| Jan Overgaard | Chairman | 0 companies |
| Niels Ebbe Valdal | Board of Directors | 0 companies |
| Kresten Mikael Valdal | Board of Directors | 0 companies |
| Ib Preben Overgaard | Chairman | 0 companies |